1. Arneric, S.P., Bannon, A.W., Briggs, C.A., Brioni, J.D., Buccafusco, J.J., Decker, M.W., Gopalakrishnan, M., Holladay, M.W., Kyncl, J., Lin, N.H., Marsh, K.G., Qiu, Y., Radek, R., Donnelly-Roberts, D.L., Sullivan, J.P., Williams, M., 1996. ABT-089: an orally active cholinergic channel modulator (ChCM) with cognitive enhancing and neuroprotective activity. In: Becker, R., Giacobini, E., Robert, P. (Eds.), Alzheimer's Disease: From Molecular Biology to Therapy. Birkhäuser, Boston.
2. Arneric, S.P., Campbell, J.E., Holladay, M.W., Johnson, P., Lin, N.H., Marsh, K.G., Petersen, B., Qiu, Y., Roberts, E.M., Rodrigues, A.D., Sullivan, J.P., Trivedi, J., Williams, M., submitted. ABT-089 [3-(2-(S)-pyrrolidinylmethoxy)-2-methyl-pyridine]: III. An orally effective cholinergic channel modulator with potential once-a-day dosing and cardiovascular safety. Drug Development Research, in press.
3. Linear system analysis in pharmacokinetics;Cutler;Journal of Pharmacokinetics and Biopharmaceutics,1978
4. Physiological parameters in laboratory animals and humans;Davies;Pharmaceutical Research,1993
5. Investigation of factors influencing release of solid drug dispersed in inert matrices;Desai;Journal of Pharmaceutical Sciences,1965